Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,822 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,088 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05109442 | Study to Assess AFM24 in Combination With Atezolizumab in Selected Advanced/Metastatic EGFR-expressing Cancers | terminated | Phase 1 / Phase 2 | 112 | Affimed GmbHINDUSTRY | 5 | Aug 20, 2025 | clinicaltrials |
| NCT03729596 | MGC018 With or Without MGA012 in Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 143 | MacroGenicsINDUSTRY | 4 | Jul 31, 2025 | clinicaltrials |
| NCT01309490 |
| Phase I/II Study of Ribavirin Given as Monotherapy in Solid Tumour Cancer Patients |
| terminated |
| Phase 1 / Phase 2 |
| 5 |
| Jewish General HospitalOTHER |
| 1 |
| Jul 29, 2025 |
| clinicaltrials |
| NCT04729348 | Pembrolizumab And Lenvatinib In Leptomeningeal Metastases | terminated | Phase 2 | 10 | Massachusetts General HospitalOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT06024174 | A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors | terminated | Phase 1 / Phase 2 | 5 | Bristol-Myers SquibbINDUSTRY | 5 | Jul 22, 2025 | clinicaltrials |
| NCT04259450 | Study to Assess AFM24 in Advanced Solid Cancers | terminated | Phase 1 / Phase 2 | 85 | Affimed GmbHINDUSTRY | 5 | Jul 17, 2025 | clinicaltrials |
| NCT04577963 | A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 52 | HutchmedINDUSTRY | 1 | Jul 14, 2025 | clinicaltrials |
| NCT04455620 | BNT151 as a Monotherapy and in Combination With Other Anti-cancer Agents in Patients With Solid Tumors | terminated | Phase 1 / Phase 2 | 49 | BioNTech SEINDUSTRY | 2 | Jul 2, 2025 | clinicaltrials |
| NCT04530487 | Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or Refractory High-Risk Solid Tumors in Pediatric and Adolescent-Young Adults | terminated | Phase 2 | 1 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 29, 2025 | clinicaltrials |
| NCT03013491 | PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas | terminated | Phase 1 / Phase 2 | 196 | CytomX TherapeuticsINDUSTRY | 6 | Jun 17, 2025 | clinicaltrials |
| NCT03094169 | AVID100 in Advanced Epithelial Carcinomas | terminated | Phase 1 / Phase 2 | 49 | Formation BiologicsINDUSTRY | 1 | Jun 11, 2025 | clinicaltrials |
| NCT04671901 | A Study of Romiplostim to Prevent Low Platelet Counts in Children and Young Adults Receiving Chemotherapy for Solid Tumors | terminated | Phase 2 | 2 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 28, 2025 | clinicaltrials |
| NCT04442126 | A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 52 | Numab Therapeutics AGINDUSTRY | 3 | May 23, 2025 | clinicaltrials |
| NCT04347226 | Anti-Interleukin-8 (Anti-IL-8) for Patients With COVID-19 | terminated | Phase 2 | 43 | Columbia UniversityOTHER | 1 | May 22, 2025 | clinicaltrials |
| NCT04171219 | Talabostat and Pembrolizumab for the Treatment of Advanced Solid Cancers | terminated | Phase 2 | 31 | M.D. Anderson Cancer CenterOTHER | 1 | May 16, 2025 | clinicaltrials |
| NCT04579757 | Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 87 | HutchmedINDUSTRY | 1 | May 8, 2025 | clinicaltrials |
| NCT04827576 | Study of Magrolimab in Patients With Solid Tumors(ELEVATELung&UC) | terminated | Phase 2 | 106 | Gilead SciencesINDUSTRY | 5 | May 8, 2025 | clinicaltrials |
| NCT05388435 | Safety, Tolerability, PK/PD & Preliminary Efficacy of SKL27969 in Advanced Solid Tumors Patients | terminated | Phase 1 / Phase 2 | 15 | SK Life Science, Inc.INDUSTRY | 1 | May 4, 2025 | clinicaltrials |
| NCT00238355 | Voriconazole and Caspofungin Acetate in Treating Invasive Fungal Infections in Patients With Weakened Immune Systems | terminated | Phase 2 | 13 | OHSU Knight Cancer InstituteOTHER | 1 | Apr 27, 2025 | clinicaltrials |
| NCT05435339 | A Study to Evaluate Safety, Tolerability, and Preliminary Effect of the GEN1053 Antibody on Malignant Solid Tumors as Monotherapy | terminated | Phase 1 / Phase 2 | 31 | GenmabINDUSTRY | 2 | Apr 22, 2025 | clinicaltrials |
| NCT03610490 | Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma | terminated | Phase 2 | 16 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 17, 2025 | clinicaltrials |
| NCT03690869 | REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma | terminated | Phase 1 / Phase 2 | 57 | Regeneron PharmaceuticalsINDUSTRY | 1 | Apr 8, 2025 | clinicaltrials |
| NCT04383210 | Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors | terminated | Phase 2 | 54 | Elevation OncologyINDUSTRY | 4 | Apr 3, 2025 | clinicaltrials |
| NCT04084366 | Phase 1/2 Study of OBI-999 in Patients With Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 44 | OBI Pharma, IncINDUSTRY | 1 | Mar 26, 2025 | clinicaltrials |
| NCT04101357 | Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411 | terminated | Phase 1 / Phase 2 | 54 | BioNTech SEINDUSTRY | 4 | Mar 18, 2025 | clinicaltrials |
| NCT05543629 | A Study of BMS-986442 With Nivolumab With or Without Chemotherapy in Solid Tumors and Non-small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 36 | Bristol-Myers SquibbINDUSTRY | 5 | Mar 18, 2025 | clinicaltrials |
| NCT05126433 | Lurbinectedin Monotherapy in Participants With Advanced or Metastatic Solid Tumors(JAZZ EMERGE201) | terminated | Phase 2 | 47 | Jazz PharmaceuticalsINDUSTRY | 1 | Feb 28, 2025 | clinicaltrials |
| NCT05559541 | Study of AK119 Combined With AK104 in Patients With Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 33 | AkesoINDUSTRY | 1 | Feb 19, 2025 | clinicaltrials |
| NCT04718675 | A Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors Including Platinum Resistant High Grade Serous Ovarian Cancer (HGSOC) | terminated | Phase 1 / Phase 2 | 135 | Kronos BioINDUSTRY | 3 | Feb 17, 2025 | clinicaltrials |
| NCT04370834 | Tocilizumab for Patients With Cancer and COVID-19 Disease | terminated | Phase 2 | 1 | National Cancer Institute (NCI)NIH | 1 | Feb 4, 2025 | clinicaltrials |
| NCT05497453 | A Phase 1/2 Study to Evaluate OTX-2002 in Patients with Hepatocellular Carcinoma and Other Solid Tumor Types Known for Association with the MYC Oncogene(MYCHELANGELO I) | terminated | Phase 1 / Phase 2 | 24 | Omega TherapeuticsINDUSTRY | 5 | Feb 3, 2025 | clinicaltrials |
| NCT05097599 | StrataPATH™ (Precision Indications for Approved Therapies)(StrataPATH) | terminated | Phase 2 | 11 | Strata OncologyINDUSTRY | 1 | Jan 8, 2025 | clinicaltrials |
| NCT05500508 | Oral AMXT 1501 Dicaprate in Combination With IV DFMO | terminated | Phase 1 / Phase 2 | 15 | Aminex Therapeutics, Inc.INDUSTRY | 2 | Dec 24, 2024 | clinicaltrials |
| NCT06524804 | A Phase Ib/II Study of BY101298 , an Oral DNA-PK Inhibitor, Combined with Radiotherapy in Patients with Malignant Solid Tumors | terminated | Phase 1 / Phase 2 | 60 | Chengdu Baiyu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Dec 18, 2024 | clinicaltrials |
| NCT04939701 | Study of ASP0739 Alone and With Pembrolizumab in Advanced Solid Tumors With NY-ESO-1 Expression Participants | terminated | Phase 1 / Phase 2 | 16 | Astellas Pharma Global Development, Inc.INDUSTRY | 1 | Dec 11, 2024 | clinicaltrials |
| NCT06290388 | Study of 23ME-01473 in Patients With Advanced Solid Malignancies | terminated | Phase 1 / Phase 2 | 5 | 23andMe, Inc.INDUSTRY | 1 | Dec 4, 2024 | clinicaltrials |
| NCT05525455 | TT-816 As Monotherapy or in Combination with a PD-1 Inhibitor in Patients with Advanced Cancers (SEABEAM) (MK3475-E88) | terminated | Phase 1 / Phase 2 | 9 | Teon Therapeutics, Inc.INDUSTRY | 1 | Nov 21, 2024 | clinicaltrials |
| NCT01217411 | RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer | terminated | Phase 1 / Phase 2 | 5 | National Cancer Institute (NCI)NIH | 1 | Nov 19, 2024 | clinicaltrials |
| NCT05394350 | A Study of MK-1088 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-1088-002) | terminated | Phase 1 / Phase 2 | 27 | Merck Sharp & Dohme LLCINDUSTRY | 5 | Nov 8, 2024 | clinicaltrials |
| NCT03379259 | Study of BGB-A333 Alone and in Combination With Tislelizumab in Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 39 | BeiGeneINDUSTRY | 3 | Oct 26, 2024 | clinicaltrials |
| NCT04690699 | LUMINOS-103: A Basket Trial of Safety & Efficacy of Lerapolturev With or Without Checkpoint Inhibitors | terminated | Phase 1 / Phase 2 | 4 | Istari Oncology, Inc.INDUSTRY | 1 | Oct 24, 2024 | clinicaltrials |
| NCT05012397 | Milademetan in Advanced/Metastatic Solid Tumors | terminated | Phase 2 | 40 | Rain Oncology IncINDUSTRY | 1 | Oct 17, 2024 | clinicaltrials |
| NCT03592264 | A Phase I/II Study of OBI-3424 in Subjects with Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 68 | OBI Pharma, IncINDUSTRY | 1 | Oct 15, 2024 | clinicaltrials |
| NCT04683939 | Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors | terminated | Phase 1 / Phase 2 | 13 | BioNTech SEINDUSTRY | 2 | Oct 2, 2024 | clinicaltrials |
| NCT05824455 | A Clinical Study of IMP4297 Capsule (JS109) Combined With Irinotecan in the Treatment of Advanced Malignant Solid Tumors | terminated | Phase 1 / Phase 2 | 4 | Shanghai Jun Pai Ying Shi Therapeutics Co., Ltd.INDUSTRY | 1 | Sep 5, 2024 | clinicaltrials |
| NCT00791154 | QUILT-2.013: First-Line Treatment for Extensive Stage Small Cell Lung Cancer(SCLC) | terminated | Phase 1 / Phase 2 | 213 | NantCell, Inc.INDUSTRY | 0 | Aug 23, 2024 | clinicaltrials |
| NCT00819169 | QUILT-3.026: AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors | terminated | Phase 1 / Phase 2 | 89 | NantCell, Inc.INDUSTRY | 0 | Aug 20, 2024 | clinicaltrials |
| NCT04393454 | Study to Evaluate the Efficacy and Safety of Sirolimus in Subjects With Metastatic, Mismatch Repair Deficient Solid Tumors After Immunotherapy | terminated | Phase 2 | 6 | Albert Einstein College of MedicineOTHER | 1 | Jul 25, 2024 | clinicaltrials |
| NCT04111107 | Precision Medicine for Patients With Identified Actionable Mutations | terminated | Phase 2 | 45 | Wake Forest University Health SciencesOTHER | 1 | Jul 3, 2024 | clinicaltrials |
Data updated 22 days agoSource updated Aug 20, 2025source: clinicaltrials